BIOCRYST PHARMACEUTICALS, INC. Share-based Payment Arrangement, Amount Capitalized
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Payment Arrangement, Amount Capitalized of $71.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-12-31 was $114.00K.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was -$43.00K.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for fiscal 2025 was $71.00K.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for fiscal 2024 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, amount capitalized for fiscal 2023 was $0.00.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $71.00K derived: sum of 2 quarters · filed 2026-02-26 | $71.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$43.00K 10-Q · filed 2025-11-04 | -$43.00K 10-Q · filed 2025-11-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |